Completed PHASE2 INTERVENTIONAL 2-arm NCT00527683

Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence

Double-Blind, Randomized, Placebo- Controlled Trial of Vigabatrin for Short Term Abstinence From Cocaine in Cocaine Dependent Parolees

Sponsor: Catalyst Pharmaceuticals, Inc.

Conditions Cocaine Dependence

Interventions Group therapy Placebo Vigabatrin

Updated 6 times since 2017 Last updated: Apr 7, 2008 Started: Apr 30, 2007 Primary completion: Nov 30, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cocaine Dependence, this trial is completed. The trial is conducted by Catalyst Pharmaceuticals, Inc. and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jun 2019 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Catalyst Pharmaceuticals, Inc.
NYU Langone Health

Data source: NYU Langone Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mexico City, Mexico